Size : | Price | Quantity | |
---|---|---|---|
5 mg | $70.00 | ||
25 mg | $276.00 |
Obatoclax (803712-79-0) is a novel Bcl-2 homology domain-3 (BH3) mimetic.1 Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC50=0.18 μM) and induces apoptosis in primary AML cells (IC50= 3.6 μM).2 Obatoclax synergizes with other agents such as chloroquine3 and cytarabine4 in cytotoxicity against a variety of cancer cells. Mediates mitochondrial stress via MCL-1 inhibition.5
References/Citations:
1) Chonghaile and Letai (2008), Mimicking the BH3 domain to kill cancer cells; Oncogene, 27 S149
2) Konopleva et al. (2008), Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res., 68 3413
3) Wang et al. (2014), Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep., 32 2789
4) Xie et al. (2015), Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol., 9 409
5) Sulkshane and Teni (2017), BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells; Oncotarget, 8 60060
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
Obatoclax (803712-79-0) is a novel Bcl-2 homology domain-3 (BH3) mimetic.1 Inhibits primary acute myeloid leukemia (AML) progenitor cell proliferation (IC50=0.18 μM) and induces apoptosis in primary AML cells (IC50= 3.6 μM).2 Obatoclax synergizes with other agents such as chloroquine3 and cytarabine4 in cytotoxicity against a variety of cancer cells. Mediates mitochondrial stress via MCL-1 inhibition.5
References/Citations:
1) Chonghaile and Letai (2008), Mimicking the BH3 domain to kill cancer cells; Oncogene, 27 S149
2) Konopleva et al. (2008), Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax); Cancer Res., 68 3413
3) Wang et al. (2014), Combination of chloroquine and GX15-070 (obatoclax) results in synergistic cytotoxicity against pancreatic cancer cells; Oncol. Rep., 32 2789
4) Xie et al. (2015), Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage; Mol. Oncol., 9 409
5) Sulkshane and Teni (2017), BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells; Oncotarget, 8 60060
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.